About Aura Biosciences
Aura Biosciences is a company based in Cambridge (United States) founded in 2007. It operates as a HealthTech. Aura Biosciences has raised $215.46 million across 11 funding rounds from investors including ARE, Citadel and LI-COR. The company has 106 employees as of December 31, 2024. Aura Biosciences offers products and services including Virus-Like Drug Conjugates (VDCs). Aura Biosciences operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Cambridge, United States
- Employees 106 as on 31 Dec, 2024
- Stage Public
-
Sectors
HealthcareTechnology
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Aura Biosciences, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-86.92 M-13.76as on Dec 31, 2024
-
EBITDA
$-94.89 M-13.38as on Dec 31, 2024
-
Total Equity Funding
$215.46 M (USD)
in 11 rounds
-
Latest Funding Round
$80.48 M (USD), Series D
Mar 22, 2021
-
Investors
ARE
& 16 more
-
Employee Count
106
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Aura Biosciences
Aura Biosciences is a publicly listed company on the NASDAQ with ticker symbol AURA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Aura Biosciences
Aura Biosciences offers a comprehensive portfolio of products and services, including Virus-Like Drug Conjugates (VDCs). The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
A platform targeting solid tumors with conjugated drugs.
Unlock access to complete
Unlock access to complete
Funding Insights of Aura Biosciences
Aura Biosciences has successfully raised a total of $215.46M across 11 strategic funding rounds. The most recent funding activity was a Series D round of $80.48 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 11
- Last Round Series D — $80.5M
-
First Round
First Round
(21 Sep 2010)
- Investors Count 17
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2021 | Amount | Series D - Aura Biosciences | Valuation | Matrix Capital Management , Citadel | |
| Jul, 2020 | Amount | Series D - Aura Biosciences | Valuation |
investors |
|
| Apr, 2019 | Amount | Series D - Aura Biosciences | Valuation | Medicxi |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Aura Biosciences
Aura Biosciences has secured backing from 17 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include ARE, Citadel and LI-COR. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage and late-stage biotech and finance companies are funded.
|
Founded Year | Domain | Location | |
|
Fintech companies are funded by Velocity Capital Fintech Ventures.
|
Founded Year | Domain | Location | |
|
Early and mid-stage life science focused VC firm investing in the US and Europe
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Aura Biosciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Aura Biosciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Aura Biosciences Comparisons
Competitors of Aura Biosciences
Aura Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Aura Biosciences
Frequently Asked Questions about Aura Biosciences
When was Aura Biosciences founded?
Aura Biosciences was founded in 2007 and raised its 1st funding round 3 years after it was founded.
Where is Aura Biosciences located?
Aura Biosciences is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Is Aura Biosciences a funded company?
Aura Biosciences is a funded company, having raised a total of $215.46M across 11 funding rounds to date. The company's 1st funding round was a Series D of $40M, raised on Sep 21, 2010.
How many employees does Aura Biosciences have?
As of Dec 31, 2024, the latest employee count at Aura Biosciences is 106.
What does Aura Biosciences do?
Aura Biosciences is engaged in creating a novel targeted oncology platform. The company utilizes Virus-Like Drug Conjugates (VDCs) to address a wide range of solid tumors. Initial efforts are concentrated on ocular and urologic oncology, including choroidal melanoma and bladder cancer. Solutions are being developed to offer new treatment options that preserve vision and improve patient outcomes in areas with unmet medical needs.
Who are the top competitors of Aura Biosciences?
Aura Biosciences's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
What products or services does Aura Biosciences offer?
Aura Biosciences offers Virus-Like Drug Conjugates (VDCs).
Is Aura Biosciences publicly traded?
Yes, Aura Biosciences is publicly traded on NASDAQ under the ticker symbol AURA.
Who are Aura Biosciences's investors?
Aura Biosciences has 17 investors. Key investors include ARE, Citadel, LI-COR, Arix Bioscience, and Matrix Capital Management.
What is Aura Biosciences's ticker symbol?
The ticker symbol of Aura Biosciences is AURA on NASDAQ.